• June 3-6, 2024
  • San Diego Convention Center, California



Origami Therapeutics, Inc.

Thursday, June 06, 2024
Start-Up Stadium Session
Company Description: Origami Therapeutics is developing curative therapies that target and degrade disease-related proteins. We are a preclinical-stage biopharmaceutical company focused on developing new therapeutics for neurodegenerative diseases, beginning with Huntington’s Disease. Our proprietary protein degraders work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins. We have built upon groundbreaking research of our founder Beth Hoffman, a veteran drug discovery scientist who discovered transformational therapeutics for cystic fibrosis, while at Vertex Pharmaceuticals. Origami is developing a broad technology platform focused on high-value targets, with the potential to deliver more potent therapies and to address the >80% of proteins that evade inhibition and have been “undruggable” by traditional approaches. Our lead programs are focused on neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD) and Huntington’s disease (HD). Our hope is to unlock the full potential of ORIGAMI protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.

Origami Therapeutics, Inc.
Company Website: https://origamitherapeutics.com/

Company HQ City

San Diego

Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Beth J Hoffman, Ph.D.
Primary Speaker
Beth Hoffman, PhD
Founder and CEO
Origami Therapeutics, Inc.
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.